Altimmune, Inc. (NASDAQ:ALT) Q2 2020 Earnings Conference Call - Final Transcript
Aug 12, 2020 • 08:30 am ET
Greetings and welcome to the Altimmune Inc. Second Quarter 2020 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]
I would now like to turn the conference over to your host Ms. Monique Kosse, Investor Relations for Altimmune. You may begin.
Thank you, Melissa, and thank you everyone for participating in today's Q2 2020 earnings conference call. Leading the call today will be Dr. Vipin Garg, Chief Executive Officer of Altimmune. Also participating on the call today is Will Brown, Chief Financial Officer; Scot Roberts, Chief Scientific Officer; and Scott Harris, Chief Medical Officer. After the prepared remarks, we will open up the call for a question-and-answer session. A press release with the Q2 2020 financial results was issued last night and can be found on the Investors page of the Company's website.
Before we begin, I would like to remind everyone that remarks about future expectations, plans and prospects constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including those related to COVID-19 and its impact on our business operations, clinical trials and results of operations.
For a discussion of some of the risks and factors that could affect the Company's future results, please see the risk factors and other cautionary statements contained in the Company's filings with the Securities and Exchange Commission. I would also direct you to read the forward-looking statement disclaimer in our earnings release issued last night and now available on our website.
Any statements made on this conference call speak only as of today's date, Wednesday, August 12, 2020 and the Company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur after or on today's date. As a reminder this conference call is being recorded and will be available for audio rebroadcast on Altimmune's website on www.altimmune.com.
With that I will now turn the call over to Vipin Garg, Chief Executive Officer of Altimmune. Vipin, please go ahead.
Vipin K. Garg
Thank you, Monique. Good morning, everyone, and thank you for joining us as we discuss our Q2 2020 financial results and corporate update. Joining me on the call today is Will Brown, our Chief Financial Officer, who will review our Q2 financial results; as well as Scot Roberts, our Chief Scientific Officer; and Scott Harris, our Chief Medical Officer. After our discussion, we will open the call for Q&A.
The first half of 2020 has been transformational for Altimmune and I'm very pleased with our progress to-date. We have made significant strides towards developing two product candidates to address the COVID-19 pandemic, a highly differentiated intranasal vaccine and a novel immunomodulatory therapeutic candidate. We secured additional government funding and capitalized the Company sufficiently to fully lean into the challenges that